retatrutide type 2 diabetes trial results Weight loss with as compared to licenced obesity Retatrutide produces up to 30.3%

Its important to follow a personalized plan created by your healthcare provider to maximize the benefits

Benefits in trials are often mediated by metabolic improvements that correlate with weight loss and improved glycemic control

People tend to lose more weight with Qsymia than with topiramate alone

Compounded formulas are essentially copies of an original drug created by a specialty pharmacy

(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers